UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Imaging Neural Activity Using Thy1-GCaMP Transgenic Mice

Neuron (Cambridge, Mass.), 2012-10, Vol.76 (2), p.297-308

2012

Volltextzugriff (PDF)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

BMJ open, 2020-10, Vol.10 (10), p.e038861-e038861

2020

Volltextzugriff (PDF)

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864231221331-17562864231221331

2024

Volltextzugriff (PDF)

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis

BMJ neurology open, 2022-06, Vol.4 (1), p.e000240-e000240

2022

Volltextzugriff (PDF)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Therapeutic advances in neurological disorders, 2021, Vol.14, p.17562864211042458-17562864211042458

2021

Volltextzugriff (PDF)

Natalizumab reduces relapse clinical severity and improves relapse recovery in MS

Multiple sclerosis and related disorders, 2014-11, Vol.3 (6), p.705-711

2014

Volltextzugriff (PDF)

Extended-interval dosing of natalizumab in NOVA – Authors' reply

Lancet neurology, 2023-03, Vol.22 (3), p.200-201

2023

Volltextzugriff (PDF)

Nicotinic control of adult-born neuron fate

Biochemical pharmacology, 2011-10, Vol.82 (8), p.820-827

2011

Volltextzugriff (PDF)

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Lancet neurology, 2017-11, Vol.16 (11), p.925-933

2017

Volltextzugriff (PDF)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Journal of neurology, neurosurgery and psychiatry, 2020-06, Vol.91 (6), p.660-668

2020

Volltextzugriff (PDF)

A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in MS Utilizing the MS PATHS Research Network (S27.001)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Neurology, 2019-10, Vol.93 (15), p.e1452

2019

Volltextzugriff (PDF)

Predicting MRI Changes in Patients with MS in the Absence of Acute Inflammation (P11-3.010)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

In a Digital Version of the 9-Hole Peg Test, Intra-Task Speed, Accounting for Variance in Distance Traveled, May be a Better Measure of MS-Related Upper-Limb Disability Than Completion Time. (P3-3.006)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Endogenous Signaling through α7-Containing Nicotinic Receptors Promotes Maturation and Integration of Adult-Born Neurons in the Hippocampus

The Journal of neuroscience, 2010-06, Vol.30 (26), p.8734-8744

2010

Volltextzugriff (PDF)

Spatiotemporal characterization of short versus long duration calcium transients in embryonic muscle and their role in myofibrillogenesis

Developmental biology, 2006-04, Vol.292 (1), p.253-264

2006

Volltextzugriff (PDF)

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing

Journal of clinical pharmacology, 2021-03, Vol.61 (3), p.339-348

2021

Volltextzugriff (PDF)

021 Determinants of natalizumab-associated PML outcomes

Journal of neurology, neurosurgery and psychiatry, 2022-06, Vol.93 (6), p.A20-A20

2022

Volltextzugriff (PDF)

Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world

Expert opinion on drug safety, 2023-10, Vol.ahead-of-print (ahead-of-print), p.1-8

2023

Volltextzugriff (PDF)

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Lancet neurology, 2022-07, Vol.21 (7), p.608-619

2022

Volltextzugriff (PDF)

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice

Multiple sclerosis, 2023-02, Vol.29 (2), p.196-205

2023

Volltextzugriff (PDF)

023 Relapse outcomes with natalizumab Q4W vs switch to Q6W

Journal of neurology, neurosurgery and psychiatry, 2022-06, Vol.93 (6), p.A20-A21

2022

Volltextzugriff (PDF)

Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-Week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (P14-3.011)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

The risk of PML from natalizumab – Authors' reply

Lancet neurology, 2019-03, Vol.18 (3), p.230-231

2019

Volltextzugriff (PDF)

Serum Neurofilament Light (sNfL) Levels in Patients with Relapsing-remitting Multiple Sclerosis (RRMS) Switching from Natalizumab Every-4-week (Q4W) Dosing to Extended Interval Dosing (EID) (2013)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

1 – 25 von 273

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(245)
Mit Volltextzugriff
(211)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(143)
Life Sciences & Biomedicine
(105)
Humans
(72)
Female
(41)
Male
(38)
Physical Sciences
(37)
Adult
(29)
Middle Aged
(24)
Animals
(23)
Aged
(20)
Neurosciences & Neurology
(19)
Biological And Medical Sciences
(18)
Multiple Sclerosis
(17)
Clinical Neurology
(14)
Monoclonal Antibodies
(14)
Natalizumab
(14)
Patients
(14)
Exact Sciences And Technology
(12)
Public, Environmental & Occupational Health
(12)
Biochemistry & Molecular Biology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Imaging Neural Activity Using Thy1-GCaMP Transgenic Mice

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Natalizumab reduces relapse clinical severity and improves relapse recovery in MS

Extended-interval dosing of natalizumab in NOVA – Authors' reply

Nicotinic control of adult-born neuron fate

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in MS Utilizing the MS PATHS Research Network (S27.001)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Predicting MRI Changes in Patients with MS in the Absence of Acute Inflammation (P11-3.010)

In a Digital Version of the 9-Hole Peg Test, Intra-Task Speed, Accounting for Variance in Distance Traveled, May be a Better Measure of MS-Related Upper-Limb Disability Than Completion Time. (P3-3.006)

Endogenous Signaling through α7-Containing Nicotinic Receptors Promotes Maturation and Integration of Adult-Born Neurons in the Hippocampus

Spatiotemporal characterization of short versus long duration calcium transients in embryonic muscle and their role in myofibrillogenesis

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing

021 Determinants of natalizumab-associated PML outcomes

Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice

023 Relapse outcomes with natalizumab Q4W vs switch to Q6W

Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-Week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (P14-3.011)

The risk of PML from natalizumab – Authors' reply

Serum Neurofilament Light (sNfL) Levels in Patients with Relapsing-remitting Multiple Sclerosis (RRMS) Switching from Natalizumab Every-4-week (Q4W) Dosing to Extended Interval Dosing (EID) (2013)

Suchergebnisse filtern